Oxurion Launches Dedicated Service Offering for GLP-1 and Peptide Therapies
The Belgian biopharmaceutical group Oxurion announced on Tuesday the launch of a dedicated service offering for GLP-1-based therapies, peptides, and biosimilar development programs. This expansion leverages the capabilities of its subsidiary Axiodis, acquired in 2025, to meet the rapidly growing market for therapeutic peptides.
A Focus on Peptide Expertise and Biosimilars
Oxurion now offers, through Axiodis, specialized services in biometrics, clinical data management, biostatistics, and regulatory-compliant data workflows. These services are intended for peptide bioequivalence studies and clinical development programs for GLP-1 therapies, biosimilars, and next-generation peptides. The proprietary Exagis platform, deployed in 12 countries, currently supports over 7,000 patient files. It covers clinical data management, biometrics and biostatistics, eCRF design and management, regulatory quality data workflows, database building and validation, as well as statistical analysis and reporting.
GLP-1 Market Acceleration and Strategic Consolidation
The expiration of patents on key molecules like semaglutide is speeding up the development of biosimilars, generics, and next-generation peptide therapies. According to an analysis from ClinicalTrials.gov, the number of phase I clinical trials involving peptides increased from 18 in 2023 to 137 in 2025, while over 2,700 peptide-related studies are currently registered globally. Industry forecasts estimate that the global market for GLP-1 receptor agonists will surpass $150 billion by 2029. Concurrently, Oxurion is advancing on another strategic acquisition in the CRO (contract research organization) sector. If realized, this transaction would complement the group's existing biometrics and data management capabilities by adding expertise in clinical operations and monitoring, thus broadening the service offering to the pharmaceutical and biotechnological sectors.
